A milestone for the therapeutic EV field: FDA approves Ryoncil, an allogeneic bone marrow-derived mesenchymal stromal cell therapy

Abstract

Small extracellular vesicles (sEVs) derived from mesenchymal stromal cells (MSCs) hold substantial promise for therapeutic applications, including immune modulation and tissue regeneration. However, challenges such as batch-to-batch variability, donor material diversity, and the lack of standardized potency testing remain significant barriers to clinical translation. The recent U.S. Food and Drug Administration (FDA) approval of Ryoncil (remestemcel-L) for steroid-refractory acute graft-versus-host disease (aGvHD) in pediatric patients represents a crucial milestone for MSC-based therapies, offering also valuable insights for the development of MSC-EV therapies. This approval highlights the critical need to address variability and standardization issues in MSC products. Strategies like immortalizing MSCs and expanding them clonally can improve scalability, consistency, and overcome limitations inherent to cellular MSC therapies. With the FDA’s decision signaling significant progress, optimizing MSC expansion protocols and refining potency testing methods will be crucial for advancing MSC-EVs as a viable therapeutic option, overcoming current challenges, and expanding clinical applications.

Keywords

Exosomes / extracellular vesicles / EVs / mesenchymal stem cells / mesenchymal stromal cells

References

[1] Ludwig AK.Exosomes: small vesicles participating in intercellular communication.Int J Biochem Cell Biol2012;44:11-5

[2] Yáñez-Mó M,Andreu Z.Biological properties of extracellular vesicles and their physiological functions.J Extracell Vesicles2015;4:27066 PMCID:PMC4433489

[3] Raposo G,Stoorvogel W.B lymphocytes secrete antigen-presenting vesicles.J Exp Med1996;183:1161-72 PMCID:PMC2192324

[4] Zitvogel L,Lozier A.Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes.Nat Med1998;4:594-600

[5] Escudier B,Chaput N.Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial.J Transl Med2005;3:10 PMCID:PMC554765

[6] Morse MA,Osada T.A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer.J Transl Med2005;3:9 PMCID:PMC551593

[7] Lamparski HG,Yao JY et al.Production and characterization of clinical grade exosomes derived from dendritic cells.J Immunol Methods2002;270:211-26

[8] Viaud S,Lapierre V.Updated technology to produce highly immunogenic dendritic cell-derived exosomes of clinical grade: a critical role of interferon-γ.J Immunother2011;34:65-75

[9] Besse B,Lapierre V.Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC.Oncoimmunology2016;5:e1071008 PMCID:PMC4839329

[10] Bruno S,Deregibus MC.Mesenchymal stem cell-derived microvesicles protect against acute tubular injury.J Am Soc Nephrol2009;20:1053-67 PMCID:PMC2676194

[11] Lai RC,Lee MM.Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury.Stem Cell Res2010;4:214-22

[12] Kordelas L,Ludwig AK.MSC-derived exosomes: a novel tool to treat therapy-refractory graft-versus-host disease.Leukemia2014;28:970-3

[13] Nassar W,Sabry D.Umbilical cord mesenchymal stem cells derived extracellular vesicles can safely ameliorate the progression of chronic kidney diseases.Biomater Res2016;20:21 PMCID:PMC4974791

[14] Warnecke A,Harre J.First-in-human intracochlear application of human stromal cell-derived extracellular vesicles.J Extracell Vesicles2021;10:e12094 PMCID:PMC8178433

[15] Sengupta V,Lazo A,Nolan A.Exosomes derived from bone marrow mesenchymal stem cells as treatment for severe COVID-19.Stem Cells Dev2020;29:747-54 PMCID:PMC7310206

[16] Chu M,Bian L.Nebulization therapy with umbilical cord mesenchymal stem cell-derived exosomes for COVID-19 pneumonia.Stem Cell Rev Rep2022;18:2152-63 PMCID:PMC9166932

[17] Zamanian MH,Hosseinkhani Z.Human placental mesenchymal stromal cell-derived small extracellular vesicles as a treatment for severe COVID-19: a double-blind randomized controlled clinical trial.J Extracell Vesicles2024;13:e12492 PMCID:PMC11270582

[18] Nazari H,Heirani-Tabasi A.Evaluating the safety and efficacy of mesenchymal stem cell-derived exosomes for treatment of refractory perianal fistula in IBD patients: clinical trial phase I.Gastroenterol Rep2022;10:goac075 PMCID:PMC9733972

[19] Pak H,Heirani-Tabasi A.Safety and efficacy of injection of human placenta mesenchymal stem cells derived exosomes for treatment of complex perianal fistula in non-Crohn’s cases: clinical trial phase I.J Gastroenterol Hepatol2023;38:539-47

[20] Ye C,Su Z.hMSC exosomes as a novel treatment for female sensitive skin: an in vivo study.Front Bioeng Biotechnol2022;10:1053679 PMCID:PMC9633936

[21] Zarrabi M,Nouri M.Allogenic mesenchymal stromal cells and their extracellular vesicles in COVID-19 induced ARDS: a randomized controlled trial.Stem Cell Res Ther2023;14:169 PMCID:PMC10294333

[22] Lightner AL,Qian S.Bone marrow mesenchymal stem cell-derived extracellular vesicle infusion for the treatment of respiratory failure from COVID-19: a randomized, placebo-controlled dosing clinical trial.Chest2023;164:1444-53 PMCID:PMC10289818

[23] Kwon HH,Lee J.Combination treatment with human adipose tissue stem cell-derived exosomes and fractional CO2 laser for acne scars: a 12-week prospective, double-blind, randomized, split-face study.Acta Derm Venereol2020;100:adv00310 PMCID:PMC9309822

[24] Witwer KW,Bruno S.Defining mesenchymal stromal cell (MSC)-derived small extracellular vesicles for therapeutic applications.J Extracell Vesicles2019;8:1609206 PMCID:PMC6493293

[25] Börger V,Anderson JD.International society for extracellular vesicles and international society for cell and gene therapy statement on extracellular vesicles from mesenchymal stromal cells and other cells: considerations for potential therapeutic agents to suppress coronavirus disease-19.Cytotherapy2020;22:482-5 PMCID:PMC7229942

[26] Gimona M,Choo ABH.Critical considerations for the development of potency tests for therapeutic applications of mesenchymal stromal cell-derived small extracellular vesicles.Cytotherapy2021;23:373-80

[27] Papait A,Gazouli M.Perinatal derivatives: how to best validate their immunomodulatory functions.Front Bioeng Biotechnol2022;10:981061 PMCID:PMC9518643

[28] Lener T,Aigner L.Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper.J Extracell Vesicles2015;4:30087 PMCID:PMC4698466

[29] Friedenstein AJ,Kulagina NN et al.Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method.Exp Hematol1974;2:83-92

[30] Friedenstein AJ,Kurolesova AI.Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues.Transplantation1968;6:230-47

[31] Pittenger MF,Beck SC.Multilineage potential of adult human mesenchymal stem cells.Science1999;284:143-7

[32] Caplan AI.Mesenchymal stem cells: building blocks for molecular medicine in the 21st century.Trends Mol Med2001;7:259-64

[33] Porada CD,Almeida-Porad G.Adult mesenchymal stem cells: a pluripotent population with multiple applications.Curr Stem Cell Res Ther2006;1:365-9

[34] Di Nicola M,Magni M.Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli.Blood2002;99:3838-43

[35] Bartholomew A,Siatskas M et al.Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo.Exp Hematol2002;30:42-8

[36] Meisel R,Laryea M,Däubener W.Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation.Blood2004;103:4619-21

[37] Le Blanc K,Sundberg B.Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells.Lancet2004;363:1439-41

[38] Galipeau J. The mesenchymal stromal cells dilemma--does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road? Cytotherapy. 2013;15:2-8.

[39] Kebriaei P,Daly A.A phase 3 randomized study of remestemcel-L versus placebo added to second-line therapy in patients with steroid-refractory acute graft-versus-host disease.Biol Blood Marrow Transplant2020;26:835-44 PMCID:PMC7060124

[40] Kurtzberg J,Carpenter P.MSB-GVHD001/002 Study GroupA phase 3, single-arm, prospective study of remestemcel-l, ex vivo culture-expanded adult human mesenchymal stromal cells for the treatment of pediatric patients who failed to respond to steroid treatment for acute graft-versus-host disease.Biol Blood Marrow Transplant2020;26:845-54 PMCID:PMC8322819

[41] Kurtzberg J,Chaudhury S.MSB-275 Study GroupStudy 275: updated expanded access program for remestemcel-L in steroid-refractory acute graft-versus-host disease in children.Biol Blood Marrow Transplant2020;26:855-64 PMCID:PMC8292970

[42] Robb KP, Galipeau J, Shi Y, Schuster M, Martin I, Viswanathan S. Failure to launch commercially-approved mesenchymal stromal cell therapies: what’s the path forward? Cytotherapy. 2024;26:413-7.

[43] Galipeau J.Mesenchymal stromal cells: clinical challenges and therapeutic opportunities.Cell Stem Cell2018;22:824-33 PMCID:PMC6434696

[44] Burnham AJ,Horwitz EM.Mesenchymal stromal cells in hematopoietic cell transplantation.Blood Adv2020;4:5877-87 PMCID:PMC7686890

[45] García-Olmo D.The history of Crohn’s perianal fistula treatment with mesenchymal stem cells: the story of darvadstrocel.Expert Opin Biol Ther2023;23:1197-202

[46] Garcia-Olmo D,Binek M.Follow-up study to evaluate the long-term safety and efficacy of darvadstrocel (mesenchymal stem cell treatment) in patients with perianal fistulizing Crohn’s disease: ADMIRE-CD phase 3 randomized controlled trial.Dis Colon Rectum2022;65:713-20 PMCID:PMC8985696

[47] Serclova Z,Chen ST.OP18 efficacy and safety of darvadstrocel treatment in patients with complex perianal fistulas and Crohn’s disease: results from the global ADMIRE-CD II phase 3 study.J Crohns Colitis2024;18:i34-5

[48] Selich A,Hass R.Massive clonal selection and transiently contributing clones during expansion of mesenchymal stem cell cultures revealed by lentiviral RGB-barcode technology.Stem Cells Transl Med2016;5:591-601 PMCID:PMC4835246

[49] Hollmann J,Goetzke R.Genetic barcoding reveals clonal dominance in iPSC-derived mesenchymal stromal cells.Stem Cell Res Ther2020;11:105 PMCID:PMC7059393

[50] Schellenberg A,Horn P.Population dynamics of mesenchymal stromal cells during culture expansion.Cytotherapy2012;14:401-11

[51] Wiese DM,Wood CA,Braid LR.Accumulating transcriptome drift precedes cell aging in human umbilical cord-derived mesenchymal stromal cells serially cultured to replicative senescence.Stem Cells Transl Med2019;8:945-58 PMCID:PMC6708062

[52] Fernandez-Rebollo E,Goetzke R.Senescence-associated metabolomic phenotype in primary and ipsc-derived mesenchymal stromal cells.Stem Cell Reports2020;14:201-9 PMCID:PMC7013233

[53] Tertel T,Arsène P,Giebel B.EV products obtained from iPSC-derived MSCs show batch-to-batch variations in their ability to modulate allogeneic immune responses in vitro.Front Cell Dev Biol2023;11:1282860 PMCID:PMC10642442

[54] Costa LA,Fraile M.Functional heterogeneity of mesenchymal stem cells from natural niches to culture conditions: implications for further clinical uses.Cell Mol Life Sci2021;78:447-67 PMCID:PMC7375036

[55] Kuçi Z,Kreyenberg H.Mesenchymal stromal cells from pooled mononuclear cells of multiple bone marrow donors as rescue therapy in pediatric severe steroid-refractory graft-versus-host disease: a multicenter survey.Haematologica2016;101:985-94 PMCID:PMC4967578

[56] Bader P,Bakhtiar S.Effective treatment of steroid and therapy-refractory acute graft-versus-host disease with a novel mesenchymal stromal cell product (MSC-FFM).Bone Marrow Transplant2018;53:852-62 PMCID:PMC6039391

[57] Doeppner TR,Görgens A.Extracellular vesicles improve post-stroke neuroregeneration and prevent postischemic immunosuppression.Stem Cells Transl Med2015;4:1131-43 PMCID:PMC4572905

[58] Ophelders DR,Jellema RK.Mesenchymal stromal cell-derived extracellular vesicles protect the fetal brain after hypoxia-ischemia.Stem Cells Transl Med2016;5:754-63 PMCID:PMC4878333

[59] Drommelschmidt K,Bendix I.Mesenchymal stem cell-derived extracellular vesicles ameliorate inflammation-induced preterm brain injury.Brain Behav Immun2017;60:220-32

[60] Gussenhoven R,Ophelders DRMG.Annexin A1 as neuroprotective determinant for blood-brain barrier integrity in neonatal hypoxic-ischemic encephalopathy.J Clin Med2019;8:137 PMCID:PMC6406389

[61] Kaminski N,Mouloud Y.Mesenchymal stromal cell-derived extracellular vesicles reduce neuroinflammation, promote neural cell proliferation and improve oligodendrocyte maturation in neonatal hypoxic-ischemic brain injury.Front Cell Neurosci2020;14:601176 PMCID:PMC7758466

[62] Wang C,Sardari M.Mesenchymal stromal cell-derived small extracellular vesicles induce ischemic neuroprotection by modulating leukocytes and specifically neutrophils.Stroke2020;51:1825-34

[63] Gregorius J,Stambouli O.Small extracellular vesicles obtained from hypoxic mesenchymal stromal cells have unique characteristics that promote cerebral angiogenesis, brain remodeling and neurological recovery after focal cerebral ischemia in mice.Basic Res Cardiol2021;116:40 PMCID:PMC8187185

[64] Van Hoecke L,Börger V.Anti-inflammatory mesenchymal stromal cell-derived extracellular vesicles improve pathology in niemann-pick type C disease.Biomedicines2021;9:1864 PMCID:PMC8698931

[65] Dumbrava DA,Börger V.Mesenchymal stromal cell-derived small extracellular vesicles promote neurological recovery and brain remodeling after distal middle cerebral artery occlusion in aged rats.Geroscience2022;44:293-310 PMCID:PMC8811093

[66] Wang C,Mohamud Yusuf A.Postischemic neuroprotection associated with anti-inflammatory effects by mesenchymal stromal cell-derived small extracellular vesicles in aged mice.Stroke2022;53:e14-8 PMCID:PMC8700303

[67] Labusek N,Mouloud Y.Hypothermia combined with extracellular vesicles from clonally expanded immortalized mesenchymal stromal cells improves neurodevelopmental impairment in neonatal hypoxic-ischemic brain injury.J Neuroinflammation2023;20:280 PMCID:PMC10680187

[68] Labusek N,Köster C.Extracellular vesicles from immortalized mesenchymal stromal cells protect against neonatal hypoxic-ischemic brain injury.Inflamm Regen2023;43:24 PMCID:PMC10108458

[69] Madel RJ,Dittrich R.Independent human mesenchymal stromal cell-derived extracellular vesicle preparations differentially attenuate symptoms in an advanced murine graft-versus-host disease model.Cytotherapy2023;25:821-36

[70] Chen TS,Yin Y.Enabling a robust scalable manufacturing process for therapeutic exosomes through oncogenic immortalization of human ESC-derived MSCs.J Transl Med2011;9:47 PMCID:PMC3100248

[71] Kraskiewicz H, Paprocka M, Bielawska-Pohl A, et al. Can supernatant from immortalized adipose tissue MSC replace cell therapy? Stem Cell Res Ther. 2020;11:29. PMCID:PMC6975034

[72] Staubach S,Tertel T.Scaled preparation of extracellular vesicles from conditioned media.Adv Drug Deliv Rev2021;177:113940